ClinicalTrials.gg
RecruitingNCT05316493Updated Jun 4, 2026

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

A Phase 2/3 interventional study of Intensive Lifestyle Intervention (ILI) and Megestrol Acetate 160 MG Oral Tablet in Atypical Endometrial Hyperplasia, Fertility Issues and Overweight and Obesity, sponsored by Xiaojun Chen. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Xiaojun Chen · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
172
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Megestrol Acetate in Endometrial Hyperplasia — 2 open to participants now, 3 under way, 1 of them phase 3. Megestrol Acetate · Endometrial Hyperplasia.

Planned enrollment
2nd of 10
172 · median 52
Started
2022
the only one that year
Phase 2/3
4 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
Xiaojun Chen

Among the 10 studies testing Megestrol Acetate in Endometrial Hyperplasia, this one is the 2nd largest by planned enrollment, is the only one that started in 2022, is one of 4 in phase 2/3, and was the 8th registered.

Endometrial Hyperplasia

110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.

Browse Endometrial Hyperplasia studies →

Open to participants now

2 of the 10 studies testing Megestrol Acetate in Endometrial Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About Megestrol Acetate

Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Endometrial Hyperplasia studies recruiting now, 9 (43%) set no upper age limit and 11 (52%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Megestrol Acetate in Endometrial Hyperplasia, or all of them as a file.
02

Study summary

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

Read the detailed description

Background:

High-efficacy progesterone, such as levonorgestrel intrauterine system (LNG-IUS), megestrol acetate (MA), and medroxyprogesterone acetate(MPA), is the first-line treatment for women with endometrial atypical hyperplasia (EAH) who want to preserve fertility. About 70% to 80% of those patients can achieve complete remission (CR) with a median CR time of about 6 months, but about 20% to 30% of those patients get no response or need longer time to get CR (over one year or even longer).

Overweight or obesity is an independent risk factor for fertility-sparing treatment response and pregnancy outcomes in young females with EAH or early endometrioid cancer (EEC). Evidence showed that obesity can cause lower CR rates and longer time to get CR and lower birth rates in EAH or EEC patients asking for conservative therapy. Weight management has been proved to improve metabolic disorders, ovarian functions, and pregnancy outcomes. Metformin, as a diabetes drug, has been proved to increase CR rates in EAH or EEC patients treated with MA for fertility. Weight management has raised more and more attention and has been proved to benefit metabolic and pregnancy outcomes. Based on previous research and published studies, the hypothesise is that weight management plus progestin therapy may raise CR rates and pregnancy outcomes in young female EAH patients asking for fertility conservation.

Enhanced lifestyle management (diet control, exercise, and daily behavioral guidance) may improve metabolic conditions, increase CR rates and pregnancy outcomes in obese EAH patients who want to preserve fertility. Till now, no similar studies were found, so this study is designed to explore the efficacy of weight control in EAH fertility-sparing patients to provide new evidence for improving conservative treatment.

Objective:

To investigate whether weight management plus LNG-IUS/MA can improve the efficacy of preserving fertility in obese EAH women who want fertility conservation.

Design:

This study is designed according to Simon's Two-Stage Design. Based on BMI and treatment plans, four single-arms are designed. This study is prospective, open-label. EAH Patients requiring conservation treatment with BMI ≥ 24 kg/m2 will be recruited in this study and they will be divided into four arms, the first group recruits overweight (24kg/ m2≤BMI\<28kg/m2) patients treated with LNG-IUS, the second group recruits overweight (24kg/ m2≤BMI\<28kg/m2) patients treated with MA, the third group recruits obese (BMI≥28kg/m2) patients treated with LNG-IUS, and the last group recruits obese (BMI≥28kg/m2) patients treated with MA. The sample size is calculated based on Simon's Two-Stage Design and previous CR rates. All enrolled patients will receive enhanced lifestyle management to control weight and take LNG-IUS/MA for treating EAH. Hysteroscopic examination, metabolic and inflammatory indicators will be performed every 12 to16 weeks while other indexes will be evaluated every month, including weight, heart rates, blood pressure, body fat tests, and so on. For the progestin efficacy evaluation, CR is defined as the remission of EAH to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease, and progressive disease (PD) is defined as disease progression in patients. Two months' maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.

Outcomes: Primary outcome is the CR rates of the four arms. Secondary outcomes include pregnancy rates, live birth rates, weight loss, insulin resistance, chronic inflammation indicators, time to achieve CR and recurrence rates, and so on. Safety and side events during the whole trial will be monitored in two years.

03

Conditions studied

  • Atypical Endometrial Hyperplasia
  • Fertility Issues
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.18 years≤age≤45years 2. (body mass index) ≥24kg/m2 3.Consent informed and signed 4. confirmed as endometrial atypical hyperplasia. Patients with endometrial specimens obtained by endometrial , diagnostic curettage or hysteroscopy and diagnosed histologically as endometrial atypical hyperplasia. If specimens are from other hospitals, they must be counseled or reconfirmed by the Department of Pathology of the Obstetrics and Gynecology Hospital of Fudan University.

5.Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements.

6.Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time.

Exclusion criteria

Exclusion Criteria:

  1. Combined with severe medical disease or liver or kidney dysfunction: (ALT) or aspartate aminotransferase (AST) level elevates to 3 times or more of the , kidney dysfunction ( \< 30 mL/min)
  2. Patients are diagnosed with other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone.
  3. Those who have received high doses of high potency progestin or oral within the last 3 months (or those on maintenance medication).
  4. Those who require hysterectomy or other methods other than conservative treatment.
  5. Known or suspected pregnancy.
  6. Those who has to use progestin.
  7. Deep vein thrombosis, stroke, myocardial infarction.
  8. Severe joint lesions that prevent walking or movement.
  9. untreated or recurrent pelvic inflammatory disease (PID)
  10. an untreated or uncontrolled pelvic infection (vaginal, cervical, uterine);
  11. Cervical dysplasia
  12. Congenital or acquired uterine abnormalities, including uterine fibroid tumors or conditions that affect the shape of the uterus
  13. allergic to the LNG-IUS components
  14. uterine cavity is too large (average uterine diameter is over 7 cm) or have a history of LNG-IUS falling out.

Notes: the last 6 criteria are only applied for patients with LNG-IUS.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    overweight MA+ILI

    enrolled overweight (24kg/m2≤BMI\<28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management

    Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Megestrol Acetate 160 MG Oral Tablet

  • Experimental
    overweight LNG-IUS+ILI

    enrolled overweight (24kg/m2≤BMI\<28kg/m2) patients will be treated with LNG-IUS plus weight management

    Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg

  • Experimental
    obese MA+ILI

    enrolled obese (BMI≥28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management

    Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Megestrol Acetate 160 MG Oral Tablet

  • Experimental
    obese LNG-IUS+ILI

    enrolled obese (BMI≥28kg/m2) patients will be treated with LNG-IUS plus weight management

    Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg

Interventions

  • BehavioralIntensive Lifestyle Intervention (ILI)

    dietary guidance, exercise guidance, lifestyle intervention

    Also known as: Weight Management

  • DrugMegestrol AcetateStudies of Megestrol AcetateMegestrol Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    enrolled participants will take Megestrol Acetate 160mg daily

    Also known as: yilizhi

  • DrugLevonorgestrelStudies of LevonorgestrelLevonorgestrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    enrolled patients will be treated with LNG-IUS.

    Also known as: manyuele

06

What researchers measure

Primary outcomes

  1. Pathological complete response (CR) rates

    The 28-week CR rates will be calculated in four arms

    Time frame: From date of recruitment until the date of CR, assessed up to 28 weeks.

Secondary outcomes

  1. Pregnancy outcomes

    For participants have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period.

    Time frame: up to 2 years after complete response of the last participant

  2. Weight change

    The investigators will record body weight every month and calculate its change in kilograms.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  3. Body composition change

    The investigators will detect body composition with InBody machine and calculate changes of the indicated indexes.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  4. Blood pressures change

    Record blood pressures (systolic and diastolic pressures) every 12-16 weeks and count the change during the trial.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  5. Heart rates change

    Record heart rates (beats per minute) every 12-16 weeks and count the change.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  6. Blood glucose change

    Assess fasting glucose levels each 3 to 4 months and calculate changes in mmol/L.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  7. Blood lipids change

    Assess blood lipids levels each 3 to 4 months and calculate changes during the trial.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  8. Insulin resistance change

    Test fasting insulin levels each 3 to 4 months, and count HOMA-IR index (Homeostatic Model Assessment for Insulin Resistance) with fasting insulin and fasting glucose as follow: Insulin (pmol/L)\*glucose (mmol/L)/22.5, and compare the HOMA-IR change during the treatment.

    Time frame: Baseline,3months and 6months after enrolled.

  9. Ovarian reserve function

    Detect serum Anti-Mullerian Hormone (AMH) each 3 or 4 months and calculate its change.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  10. Quality of life change

    Collect the questionnaire SF-36 and count scores change through conservative treatment.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  11. Impact of Weight on Quality of Life

    Collect questionnaire IWQOL- LITE and count scores change through conservative treatment.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  12. Physical activities change

    Collect physical activities questionnaire(IPAQ) and compare scores changes through conservative treatment.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  13. Chronic inflammatory index (TNF-α) change

    The investigators will detect the levels of TNF-α (fmol/ml) in serum and calculate changes through the whole treatment period.

    Time frame: baseline, 3 months and 6 months after treatment.

  14. Chronic inflammatory index (IL-1) change

    The investigators will detect serum index IL-1 in U/ml and calculate changes through the whole treatment period.

    Time frame: baseline, 3 months and 6 months after treatment.

  15. Chronic inflammatory index (IL-6) change

    The investigators will detect serum index IL-6 in U/ml and calculate changes through the whole treatment period.

    Time frame: baseline, 3 months and 6 months after treatment.

  16. Time of pathological complete response (CR)

    Time of histologic regression from EAH to proliferative or secretory endometrium

    Time frame: From date of recruitment until the date of CR, assessed up to 2 years.

  17. Incidence of adverse events

    Adverse events related with MA, LNG-IUS and weight control. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 will be recorded, as well as incidence of adverse events.

    Time frame: From date of recruitment until the date of CR, assessed up to 2 years.

  18. Relapse rates

    All enrolled patients will be followed up for 2 years. During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then the investigators can get the relapse rates.

    Time frame: up to 2 years after the treatment for each patient

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Feb 2026, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 7, 2022
StartActual
Jun 13, 2022
Primary completionActual
Feb 28, 2026
CompletionEst.
Feb 28, 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05316493
Lead sponsor
Xiaojun Chen
Responsible party
Xiaojun Chen (Principal Investigator, Fudan University) — Sponsor-investigator
First posted
Apr 7, 2022
Start date
Jun 13, 2022
Primary completion
Feb 28, 2026
Completion
Feb 28, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

WEIWEI SHAN, PhD
Contact
danweiwei7468@fckyy.org.cn
8613817813106
XIAOJUN CHEN, PhD
Contact
cxjlhjj@163.com
8613601680784
XIAOJUN CHEN, PhD
principal investigator · Obstetrics & Gynecology Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Megestrol Acetate · Levonorgestrel

Start the discussion